Abstract
Seventy two patients admitted to the Intensive Care Unit following ingestion of organophosphorus compounds were studied prospectively with two different doses of pralidoxime (PAM). One group received 1 gm immediately after admission and no further PAM and the other group received infusion of PAM, 1 gm 8 hourly for four days (total 12 gms). The incidence of type II paralysis or intermediate syndrome was 47%. We observed a higher incidence in the 4 days of infusion of PAM group (61%) (20 patients) as compared to the single Bolus dose group (39%) (13 patients). Relative risk 1.48 (confidence interval = 0.9-2.4).
Publication types
-
Clinical Trial
-
Comparative Study
-
Randomized Controlled Trial
MeSH terms
-
Adult
-
Cholinesterase Reactivators / administration & dosage*
-
Cholinesterase Reactivators / adverse effects
-
Dose-Response Relationship, Drug
-
Double-Blind Method
-
Drug Administration Schedule
-
Drug Overdose / drug therapy*
-
Female
-
Humans
-
Infusions, Intravenous
-
Male
-
Organophosphate Poisoning*
-
Paralysis / chemically induced*
-
Paralysis / drug therapy
-
Pralidoxime Compounds / administration & dosage*
-
Pralidoxime Compounds / adverse effects
-
Prospective Studies
-
Respiratory Paralysis / chemically induced*
-
Respiratory Paralysis / drug therapy
-
Syndrome
Substances
-
Cholinesterase Reactivators
-
Pralidoxime Compounds
-
pralidoxime